Letermovir for prevention of recurrent CMV in high-risk allogeneic hematopoietic cell transplant (HCT) recipients.

IF 3.6 3区医学 Q2 HEMATOLOGY Transplantation and Cellular Therapy Pub Date : 2024-12-17 DOI:10.1016/j.jtct.2024.12.010

Gyuri Han, Anat Stern, Yeon Joo Lee, Yuxuan Li, Parastoo B Dahi, Roni Tamari, Boglarka Gyurkocza, Ann A Jakubowski, Esperanza B Papadopoulos, Brian Shaffer, Miguel-Angel Perales, Karam M Obeid, Jo-Anne H Young, Genovefa A Papanicolaou

{"title":"Letermovir for prevention of recurrent CMV in high-risk allogeneic hematopoietic cell transplant (HCT) recipients.","authors":"Gyuri Han, Anat Stern, Yeon Joo Lee, Yuxuan Li, Parastoo B Dahi, Roni Tamari, Boglarka Gyurkocza, Ann A Jakubowski, Esperanza B Papadopoulos, Brian Shaffer, Miguel-Angel Perales, Karam M Obeid, Jo-Anne H Young, Genovefa A Papanicolaou","doi":"10.1016/j.jtct.2024.12.010","DOIUrl":null,"url":null,"abstract":"Background: We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence.Methods: Open-label study conducted at Memorial Sloan Kettering Cancer Center and the University of Minnesota. Patients with clinically significant CMV infection (cs-CMVi) and ≥1 high-risk criteria for CMV who achieved viral suppression with standard CMV antivirals, received letermovir (LTV) secondary prophylaxis for up to 14 weeks. The primary endpoint was cs-CMVi at week 14. Secondary endpoints included, LTV resistance, CMV end-organ disease (EOD), CMV-related death and LTV related Adverse Events (AE) at week 14.Results: Thirty-six patients were analyzed (CMV seropositive 33, T-cell depleted HCT 25, cord blood allograft 5) were analyzed. By week 14, 5 patients met the primary endpoint of cs-CMVi, for a cumulative incidence of 14.9% (95% confidence interval 2.6 - 27.1). Four patients developed LTV breakthrough cs-CMVi (including 2 patients with confirmed LTV resistance). The remaining patient developed rebound cs-CMVI after premature discontinuation of LTV due to enrollment in a clinical trial. There were no cases of CMV EOD or CMV-related deaths or LTV related AE by week 14 or by week 24.Conclusions: Our data supports that LTV secondary prophylaxis is safe and effective in high-risk HCT recipients.","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2024.12.010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence.

Methods: Open-label study conducted at Memorial Sloan Kettering Cancer Center and the University of Minnesota. Patients with clinically significant CMV infection (cs-CMVi) and ≥1 high-risk criteria for CMV who achieved viral suppression with standard CMV antivirals, received letermovir (LTV) secondary prophylaxis for up to 14 weeks. The primary endpoint was cs-CMVi at week 14. Secondary endpoints included, LTV resistance, CMV end-organ disease (EOD), CMV-related death and LTV related Adverse Events (AE) at week 14.

Results: Thirty-six patients were analyzed (CMV seropositive 33, T-cell depleted HCT 25, cord blood allograft 5) were analyzed. By week 14, 5 patients met the primary endpoint of cs-CMVi, for a cumulative incidence of 14.9% (95% confidence interval 2.6 - 27.1). Four patients developed LTV breakthrough cs-CMVi (including 2 patients with confirmed LTV resistance). The remaining patient developed rebound cs-CMVI after premature discontinuation of LTV due to enrollment in a clinical trial. There were no cases of CMV EOD or CMV-related deaths or LTV related AE by week 14 or by week 24.

Conclusions: Our data supports that LTV secondary prophylaxis is safe and effective in high-risk HCT recipients.

查看原文